Antihelicase action of CI-958, a new drug for prostate cancer.

abstract：INTRODUCTION:Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment. MATERIAL AND METHODS:A retrospective review of 183 patients submitted to second-line thera...

journal_title：Cancer chemotherapy and pharmacology

authors： Reni M,Berardi R,Mambrini A,Pasetto L,Cereda S,Ferrari VD,Cascinu S,Cantore M,Mazza E,Grisanti S

更新日期：2008-09-01 00:00:00

abstract：:Pyrazine diazohydroxide (sodium salt, NSC 361456; PZDH) is a new antitumor drug with relatively broad activity in initial evaluations against murine leukemias, solid tumors, and two human tumor xenografts in vivo. The present studies were designed to address questions about PZDH activity on different treatment schedul...

journal_title：Cancer chemotherapy and pharmacology

authors： Harrison SD Jr,Plowman J,Dykes DJ,Waud WR,Griswold DP Jr

更新日期：1990-01-01 00:00:00

abstract：:The toxic effect of 3'-deoxyadenosine N1-oxide (3'-dANO) on mice, on their different organs, and on Ehrlich ascites tumor cells was studied. In both healthy and tumour-bearing animals, the lethal dose for 10% of the mice receiving i.p. injections (LD10) of 3'-dANO was estimated to be about 300 mg/kg x 4 days in one mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Svendsen KR,Overgaard-Hansen K,Frederiksen S,Engelholm SA,Pedersen NT,Vindeløv LL

更新日期：1992-01-01 00:00:00

abstract：OBJECTIVE:To study the pharmacokinetics of neamine in rats and to evaluate its anti-cervical cancer activity. METHODS:The plasma level of neamine was determined by HPLC-ELSD. Pharmacokinetic parameters were calculated using DAS 2.0 software. Tissue microarray analysis was conducted to examine angiogenin (ANG) expressi...

journal_title：Cancer chemotherapy and pharmacology

authors： Liu Y,Zhang X,An S,Wu Y,Hu G,Wu Y

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:The aim of this study was to investigate the relationship between changes in IL-1β expression and intestinal apoptosis after chemotherapy. And we further determine whether interleukin-1 receptor antagonist (IL-1Ra) reduces apoptosis in vivo after 5-fluorouracil (5-FU) chemotherapy in the small intestine. METHO...

journal_title：Cancer chemotherapy and pharmacology

authors： Wu ZQ,Han XD,Wang Y,Yuan KL,Jin ZM,Di JZ,Yan J,Pan Y,Zhang P,Huang XY,Wang ZG,Zheng Q

更新日期：2011-07-01 00:00:00

abstract：:Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffet E,Khelfaoui F,Philip I,Biron P,Brunat-Mentigny M,Philip T

更新日期：1997-01-01 00:00:00

abstract：:Patients with carcinoid syndrome usually die from carcinomatosis, rather than the pharmacological effects of the tumour. Functioning carcinoid tumours are resistant to radiotherapy. Twenty-four different cytotoxic drugs or combinations have been used to treat the carcinoid syndrome, but only actinomycin D, cyclophosph...

journal_title：Cancer chemotherapy and pharmacology

authors： Harris AL

更新日期：1981-01-01 00:00:00

abstract：:Forty-one previously treated patients with advanced Hodgkin's disease were treated with a combination chemotherapy regimen -- ABVD (adriamycin, bleomycin, velbe/vincristine, imidazole carboxamide). Complete remission was achieved in three patients (7%), partial remission in 23 (56%), and no response in 15 patients (37...

journal_title：Cancer chemotherapy and pharmacology

authors： Sutcliffe SB,Wrigley PF,Stansfeld AG,Malpas JS

更新日期：1979-01-01 00:00:00

abstract：PURPOSE:Imatinib mesylate (Imatinib), clinically employed for chronic myeloid leukemia and gastrointestinal stromal tumors, is a selective inhibitor of the tyrosine kinases, c-abl, c-kit and PDGFRs. Due to the frequent expression of these genes in breast cancer cells, the clinical efficacy of Imatinib has recently been...

journal_title：Cancer chemotherapy and pharmacology

authors： Rappa G,Anzanello F,Lorico A

更新日期：2011-04-01 00:00:00

abstract：:Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

journal_title：Cancer chemotherapy and pharmacology

authors： Hopkins JJ,Sawyer MB

更新日期：2018-07-01 00:00:00

abstract：PURPOSE:The safety of S-1 in recurrent colorectal cancer patients with chronic myeloid leukemia (CML) treated with dasatinib has not been established. We evaluated the safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with CML treated with dasatinib. PATIENT:A 70-year-old man had undergone surgery...

journal_title：Cancer chemotherapy and pharmacology

authors： Sueda T,Kudo T,Sakai D,Uemura M,Nishimura J,Hata T,Takemasa I,Mizushima T,Yamamoto H,Ezoe S,Matsumoto K,Doki Y,Mori M,Satoh T

更新日期：2014-12-01 00:00:00

abstract：:In five cancer patients we have determined the pharmacokinetics of 4'-deoxydoxorubicin (4'-DOX), its alcoholic metabolite 4'-deoxydoxorubicinol and the occurrence of circulating 7-deoxyaglycone metabolites. The 7-deoxyaglycone of the alcohol metabolite, the major aglycone of Adriamycin (ADR) present in man, was not de...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,Kerr DJ,Kaye SB

更新日期：1987-01-01 00:00:00

abstract：:The ubiquitin-proteasome system (UPS) is an important system that regulates the balance of intracellular proteins, and it is involved in the regulation of multiple vital biological processes. The approval of bortezomib for relapsed and refractory multiple myeloma has proven that agents targeting the UPS have the poten...

journal_title：Cancer chemotherapy and pharmacology

authors： Ying J,Zhang M,Qiu X,Lu Y

更新日期：2018-05-01 00:00:00

abstract：:Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby research efforts are direct...

journal_title：Cancer chemotherapy and pharmacology

authors： Hausheer FH,Kochat H,Parker AR,Ding D,Yao S,Hamilton SE,Petluru PN,Leverett BD,Bain SH,Saxe JD

更新日期：2003-07-01 00:00:00

abstract：:The subjects were 35 patients with unresectable hepatocellular carcinoma. The patients were divided into a transcatheter arterial embolization group (TAE group, 18 cases) and a combination therapy group receiving both TAE and percutaneous ethanol injection therapy (TAE+PEIT group, 17 cases). The 50% survival period wa...

journal_title：Cancer chemotherapy and pharmacology

authors： Tateishi H,Kinuta M,Furukawa J,Takata N,Maruyama H,Oi H,Yayoi E,Okamura J

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Transcatheter arterial chemoembolization (TACE) causes damage to liver function and decreases the activity of cytochrome P450 in patients with hepatocellular carcinoma (HCC). But there was no report on whether the activity of Phase II conjugating enzymes was affected in HCC patients after TACE treatment. The pu...

journal_title：Cancer chemotherapy and pharmacology

authors： Zhang Y,Jia Y,Liu X,Liu L,Wang Q,Wen A

更新日期：2010-01-01 00:00:00

abstract：PURPOSE:Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors. ME...

journal_title：Cancer chemotherapy and pharmacology

authors： Nemunaitis J,Young A,Ejadi S,Miller W,Chen LC,Nichols G,Blotner S,Vazvaei F,Zhi J,Razak A

更新日期：2018-03-01 00:00:00

abstract：PURPOSE:Extrapulmonary neuroendocrine carcinomas (EPNEC) are rarely observed and are associated with poor outcomes. Based on the clinicopathological similarity, treatment used for small cell lung carcinoma has also been employed for EPNEC, but the response to such therapy has not been well examined. The goal of this st...

journal_title：Cancer chemotherapy and pharmacology

authors： Nio K,Arita S,Isobe T,Kusaba H,Kohashi K,Kajitani T,Tamura S,Hirano G,Mitsugi K,Makiyama A,Esaki T,Ariyama H,Oda Y,Akashi K,Baba E

更新日期：2015-04-01 00:00:00

abstract：PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive, lethal, and heterogeneous subtype of breast cancers, tending to have lower 5-year survival rates than other BC subtypes in response to conventional chemotherapies. This study's aim was to identify advanced regimens to effectively control TNBC tumor developm...

journal_title：Cancer chemotherapy and pharmacology

authors： Pattarawat P,Wallace S,Pfisterer B,Odoi A,Wang HR

更新日期：2020-01-01 00:00:00

abstract：:The cytotoxic effects of ketoconazole, an antifungal agent known to have some activity against human prostate cancer, adrenal cancer, and male metastatic breast cancer, were evaluated using colony-growth and clonogenic assays in eight malignant cell lines. The cytotoxicity of ketoconazole showed a dose- and time-depen...

journal_title：Cancer chemotherapy and pharmacology

authors： Rochlitz CF,Damon LE,Russi MB,Geddes A,Cadman EC

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:It has recently been recognised that anticancer chemotherapy can elicit an immunogenic form of apoptosis characterised by the exposure of calreticulin (CRT) on the surface of dying tumour cells, entailing an immune response that contributes to the therapeutic outcome. CRT exposure has been found to be induced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Sonnemann J,Gressmann S,Becker S,Wittig S,Schmudde M,Beck JF

更新日期：2010-08-01 00:00:00

abstract：:A 72-year-old male with a lymphoma and obstructive jaundice received 900 mg cyclophosphamide IV as a part of a chemotherapeutic regimen whilst external biliary drainage was in progress. Plasma, urinary, and biliary pharmacokinetics of cyclophosphamide and nitrobenzylpyridine (NBP)-alkylating metabolites were studied. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Dooley JS,James CA,Rogers HJ,Stuart-Harris R

更新日期：1982-01-01 00:00:00

abstract：:A total of 20 adults patients presenting with previously untreated lymphoblastic lymphoma underwent an intensive chemotherapy protocol. Either the BACOP or the m-BACOD regimen was used for induction. If the patients achieved a complete clinical remission (CR) after three courses, they were given intensive consolidatio...

journal_title：Cancer chemotherapy and pharmacology

authors： Liang R,Todd D,Chan TK,Chiu E,Lie A,Ho FC,Loke SL

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:To evaluate the plasma protein binding and pharmacokinetics of prednisolone during therapeutic use in children with acute lymphoblastic leukemia (ALL) using the population approach. METHODS:A two-compartment pharmacokinetic model was used to describe data from 23 children with ALL (aged 2-15 years). Prednisolo...

journal_title：Cancer chemotherapy and pharmacology

authors： Petersen KB,Jusko WJ,Rasmussen M,Schmiegelow K

更新日期：2003-06-01 00:00:00

abstract：:We studied serum lipid and lipoprotein changes occurring during chemotherapy in 57 patients with chemosensitive cancers, including 18 malignant lymphomas, 18 breast carcinomas, 14 small-cell lung carcinomas, and 7 urothelial-cell carcinomas. Patients who responded favorably to chemotherapy demonstrated a significant i...

journal_title：Cancer chemotherapy and pharmacology

authors： Alexopoulos CG,Pournaras S,Vaslamatzis M,Avgerinos A,Raptis S

更新日期：1992-01-01 00:00:00

abstract：:Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

journal_title：Cancer chemotherapy and pharmacology

authors： Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

更新日期：1996-01-01 00:00:00

abstract：:When tumor cell density increases, the cytotoxic activity of certain anticancer agents, such as vincristine (VCR) and doxorubicin (DXR), progressively decreases. This phenomenon is termed the inoculum effect. Since VCR and DXR are less active in an acidic environment, we questioned whether the inoculum effects could h...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi H,Takemura Y,Ohnuma T

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:To determine the growth inhibitory effects of mifepristone on endometrial cancer cell growth and evaluate its effect on apoptosis using HEC-1-A and Ishikawa human endometrial cancer cell lines. METHODS:The human endometrial cancer cell lines, HEC-1-A and Ishikawa, were cultured in vitro. MTT assays were comple...

journal_title：Cancer chemotherapy and pharmacology

authors： Navo MA,Smith JA,Gaikwad A,Burke T,Brown J,Ramondetta LM

更新日期：2008-08-01 00:00:00

abstract：PURPOSE:This phase I trial evaluated the maximum tolerated dose, safety and preliminary efficacy of lapatinib, a HER1, HER2 dual kinase inhibitor plus bortezomib, a proteasome inhibitor, in adult patients with advanced malignancies. METHODS:Patients were enrolled in a standard 3 + 3 design with lapatinib (L) 750, 1000...

journal_title：Cancer chemotherapy and pharmacology

authors： Lynce F,Wang H,Petricoin EF,Pohlmann PR,Smaglo B,Hwang J,He AR,Subramaniam DS,Deeken J,Marshall J,Pishvaian MJ

更新日期：2019-11-01 00:00:00

abstract：:The discovery of targetable mutations, which cause gene rearrangement, led to a major advancement in the treatment of patients with non-small cell lung cancer (NSCLC), and cancers with such mutations can be paired with drugs which specifically target them. c-ros oncogene (ROS1) positive NSCLC is one molecular subtype ...

journal_title：Cancer chemotherapy and pharmacology

authors： Roys A,Chang X,Liu Y,Xu X,Wu Y,Zuo D

更新日期：2019-10-01 00:00:00